Oaktree Acquisition Corp. III Life Sciences reported a net loss reduction in activity for the first quarter of 2026, recording net income of $1.39M, or $0.06 diluted EPS, compared with net income of $1.66M, or $0.07 diluted EPS, in the year-ago quarter. The company had no operating revenues for the period and generated non-operating interest income from trust account investments.
Financial Highlights
- Net income was $1.39M for Q1 2026, down from $1.66M in Q1 2025 ( (16.0% )).
- Diluted EPS was $0.06 for Q1 2026, versus $0.07 in Q1 2025 ( (14.3% )).
- Revenue: Not presented for the quarter (no operating revenues; interest income is non‑operating).
Business Highlights
- Operational focus remains on completing an initial business combination; management is engaged in target identification, due diligence and deal structuring activities.
- The company has not generated operating revenues to date and earns only non‑operating interest income from trust account investments.
- Ongoing costs reflect public-company and transaction-related expenses incurred while pursuing a business combination.
- Substantially all trust funds and earned interest are reserved to fund a post-combination business and its operations.
- Plans to complete a business combination by Oct. 25, 2026; the company may seek extensions and additional capital if required.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.